Works matching AU FRIAS, JUAN P.

Results: 73

Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes.

Published in:

PLoS ONE, 2018, v. 13, n. 9, p. 1, doi. 10.1371/journal.pone.0203946

By:

Henry, Robert R.;
Frias, Juan P.;
Walsh, Brandon;
Skare, Sharon;
Hemming, John;
Burns, Colleen;
Bicsak, Thomas A.;
Baron, Alain;
Fineman, Mark

Publication type:

Article

Fatty Acid-Induced Insulin Resistance: Decreased Muscle PI3K Activation But Unchanged Akt Phosphorylation.

Published in:

Journal of Clinical Endocrinology & Metabolism, 2002, v. 87, n. 1, p. 226, doi. 10.1210/jcem.87.1.8187

By:

KRUSZYNSKA, YOLANTA T.;
WORRALL, DOROTHY SEARS;
OFRECIO, JACHELLE;
FRIAS, JUAN P.;
MACARAEG, GINA;
OLEFSKY, JERROLD M.

Publication type:

Article

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.

Published in:

Diabetologia, 2020, v. 63, n. 3, p. 473, doi. 10.1007/s00125-019-05065-8

By:

McCrimmon, Rory J.;
Catarig, Andrei-Mircea;
Frias, Juan P.;
Lausvig, Nanna L.;
le Roux, Carel W.;
Thielke, Desirée;
Lingvay, Ildiko

Publication type:

Article

Effect of iGlarLixi on continuous glucose monitoring—measured time in range in insulin‐naive adults with suboptimally controlled type 2 diabetes.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 4, p. 2173, doi. 10.1111/dom.16214

By:

Frías, Juan P.;
Ratzki‐Leewing, Alexandria;
Dex, Terry;
Meneghini, Luigi;
Rodrigues, Amélie;
Shah, Viral N.

Publication type:

Article

Cardiovascular efficacy and safety of antidiabetic agents: A network meta‐analysis of randomized controlled trials.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3560, doi. 10.1111/dom.15251

By:

Sohn, Minji;
Frias, Juan P.;
Lim, Soo

Publication type:

Article

Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2805, doi. 10.1111/dom.15168

By:

Saxena, Aditi R.;
Frias, Juan P.;
Gorman, Donal N.;
Lopez, Rene N.;
Andrawis, Nabil;
Tsamandouras, Nikolaos;
Birnbaum, Morris J.

Publication type:

Article

A microbiome‐targeting fibre‐enriched nutritional formula is well tolerated and improves quality of life and haemoglobin A1c in type 2 diabetes: A double‐blind, randomized, placebo‐controlled trial.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1203, doi. 10.1111/dom.14967

By:

Frias, Juan P.;
Lee, Martin L.;
Carter, Matthew M.;
Ebel, Emily R.;
Lai, Ren‐Hau;
Rikse, Lars;
Washington, Marc E.;
Sonnenburg, Justin L.;
Damman, Christopher J.

Publication type:

Article

A 96‐week, double‐blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 1, p. 293, doi. 10.1111/dom.14875

By:

Halvorsen, Yuan‐Di;
Lock, John Paul;
Frias, Juan P.;
Tinahones, Francisco José;
Dahl, Dominik;
Conery, Annie L.;
Freeman, Mason W.

Publication type:

Article

iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 1, p. 68, doi. 10.1111/dom.14844

By:

McCrimmon, Rory J.;
Cheng, Alice Y.Y.;
Galstyan, Gagik;
Djaballah, Khier;
Li, Xuan;
Coudert, Mathieu;
Frias, Juan P.

Publication type:

Article

Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat MRI substudy.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 61, doi. 10.1111/dom.14548

By:

Frías, Juan P.;
Maaske, Jill;
Suchower, Lisa;
Johansson, Lars;
Hockings, Paul D.;
Iqbal, Nayyar;
Wilding, John P. H.

Publication type:

Article

Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2819, doi. 10.1111/dom.14533

By:

Frias, Juan P.;
Bonora, Enzo;
Cox, David A.;
Bethel, M. Angelyn;
Kwan, Anita Y.M.;
Raha, Sohini;
Malik, Raleigh E.

Publication type:

Article

Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 10, p. 2279, doi. 10.1111/dom.14469

By:

Frias, Juan P.;
Bonora, Enzo;
Nevárez Ruiz, Luis;
Hsia, Stanley H.;
Jung, Heike;
Raha, Sohini;
Cox, David A.;
Bethel, M. Angelyn;
Konig, Manige

Publication type:

Article

Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 10, p. 2242, doi. 10.1111/dom.14465

By:

Bonora, Enzo;
Frias, Juan P.;
Tinahones, Francisco J.;
Van, Joanna;
Malik, Raleigh E.;
Yu, Zhuoxin;
Mody, Reema;
Bethel, Angelyn;
Kwan, Anita Y. M.;
Cox, David A.

Publication type:

Article

Efficacy and safety of dual add‐on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52‐week, randomized, active‐controlled trial

Published in:

Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1083, doi. 10.1111/dom.13997

By:

Frias, Juan P.;
Gonzalez‐Galvez, Guillermo;
Johnsson, Eva;
Maaske, Jill;
Testa, Marcia A.;
Simonson, Donald C.;
Dronamraju, Nalina;
Garcia‐Sanchez, Ricardo;
Peters, Anne L.

Publication type:

Article

Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials.

Published in:

Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 303, doi. 10.1111/dom.13896

By:

Aroda, Vanita R.;
Capehorn, Matthew S.;
Chaykin, Louis;
Frias, Juan P.;
Lausvig, Nanna L.;
Macura, Stanislava;
Lüdemann, Jörg;
Madsbad, Sten;
Rosenstock, Julio;
Tabak, Omur;
Tadayon, Sayeh;
Bain, Stephen C.

Publication type:

Article

Hormone‐substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active‐controlled DURATION‐8 study.

Published in:

Diabetes, Obesity & Metabolism, 2020, v. 22, n. 1, p. 99, doi. 10.1111/dom.13870

By:

Ferrannini, Ele;
Baldi, Simona;
Frías, Juan P.;
Guja, Cristian;
Hardy, Elise;
Repetto, Enrico;
Jabbour, Serge A.;
DeFronzo, Ralph A.

Publication type:

Article

Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real‐world study.

Published in:

Diabetes, Obesity & Metabolism, 2019, v. 21, n. 9, p. 2123, doi. 10.1111/dom.13793

By:

Sullivan, Sean D.;
Nicholls, Charlie J.;
Gupta, Rishab A.;
Menon, Arjun A.;
Wu, Jasmanda;
Westerbacka, Jukka;
Bosnyak, Zsolt;
Frias, Juan P.;
Bailey, Timothy S.

Publication type:

Article

Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin.

Published in:

Diabetes, Obesity & Metabolism, 2019, v. 21, n. 9, p. 2048, doi. 10.1111/dom.13764

By:

Frias, Juan P.;
Wynne, Alan G.;
Matyjaszek‐Matuszek, Beata;
Bartaskova, Dagmar;
Cox, David A.;
Woodward, Brad;
Li, Ying G.;
Tham, Lai S.;
Milicevic, Zvonko

Publication type:

Article

Double‐blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT‐M study.

Published in:

Diabetes, Obesity & Metabolism, 2019, v. 21, n. 5, p. 1128, doi. 10.1111/dom.13626

By:

Frias, Juan P.;
Zimmer, Zachary;
Lam, Raymond L.H.;
Amorin, Guillermo;
Ntabadde, Catherine;
Iredale, Carol;
O'Neill, Edward A.;
Engel, Samuel S.;
Kaufman, Keith D.;
Makimura, Hideo;
Crutchlow, Michael F.

Publication type:

Article

Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy‐confirmed nonalcoholic steatohepatitis.

Published in:

Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 10, p. 1005, doi. 10.1111/apt.17709

By:

Alkhouri, Naim;
Lazas, Donald;
Loomba, Rohit;
Frias, Juan P.;
Feng, Shibao;
Tseng, Leo;
Balic, Kemal;
Agollah, Germaine D.;
Kwan, Tinna;
Iyer, Janani S.;
Morrow, Linda;
Mansbach, Hank;
Margalit, Maya;
Harrison, Stephen A.

Publication type:

Article

Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes.

Published in:

2006

By:

Pullman, John;
Darsow, Tamara;
Frias, Juan P.

Publication type:

journal article

Decreased susceptibility to fatty acid-induced peripheral tissue insulin resistance in women.

Published in:

2001

By:

Frias, Juan P.;
Macaraeg, Gina B.;
Ofrecio, Jachelle;
Yu, Joseph G.;
Olefsky, Jerrold M.;
Kruszynska, Yolanta T.;
Frias, J P;
Macaraeg, G B;
Ofrecio, J;
Yu, J G;
Olefsky, J M;
Kruszynska, Y T

Publication type:

journal article

Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes.

Published in:

Diabetes/Metabolism Research & Reviews, 2008, v. 24, n. 2, p. 103, doi. 10.1002/dmrr.765

By:

Ceriello, Antonio;
Lush, Cameron W.;
Darsow, Tamara;
Piconi, Ludovica;
Corgnali, Maddelena;
Nanayakkara, Nuwan;
Frias, Juan P.;
Maggs, David

Publication type:

Article

Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.

Published in:

2000

By:

Frias, Juan P,;
Yu, Joseph G.;
Kruszynska, Yolanta T.;
Olefsky, Jerrold M.;
Frias, J P;
Yu, J G;
Kruszynska, Y T;
Olefsky, J M

Publication type:

journal article

Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times Relative to Subcutaneous Injection of Pramlintide in Subjects With Type 2 Diabetes.

Published in:

Journal of Clinical Pharmacology, 2007, v. 47, n. 7, p. 798, doi. 10.1177/0091270007300949

By:

Kellmeyer, Terrie A.;
Kesty, Nicole C.;
Yan Wang;
Frias, Juan P.;
Fineman, Mark S.

Publication type:

Article

Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial.

Published in:

JAMA Network Open, 2023, v. 6, n. 5, p. e2314493, doi. 10.1001/jamanetworkopen.2023.14493

By:

Saxena, Aditi R.;
Frias, Juan P.;
Brown, Lisa S.;
Gorman, Donal N.;
Vasas, Szilard;
Tsamandouras, Nikolaos;
Birnbaum, Morris J.

Publication type:

Article

Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).

Published in:

Journal of Clinical Endocrinology & Metabolism, 2024, v. 109, n. 7, p. 1745, doi. 10.1210/clinem/dgae038

By:

Frias, Juan P;
Block, Christophe De;
Brown, Katelyn;
Wang, Hui;
Thomas, Melissa K;
Zeytinoglu, Meltem;
Maldonado, Juan M

Publication type:

Article

Results of a Study Comparing Glycated Albumin to Other Glycemic Indices.

Published in:

2019

By:

Desouza, Cyrus V;
Holcomb, Richard G;
Rosenstock, Julio;
Frias, Juan P;
Hsia, Stanley H;
Klein, Eric J;
Zhou, Rong;
Kohzuma, Takuji;
Fonseca, Vivian A

Publication type:

journal article

Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.

Published in:

2019

By:

Schmider, Wolfgang;
Niemoeller, Elisabeth;
Belder, Rene;
Lee, Michelle;
Souhami, Elisabeth;
Frias, Juan P.

Publication type:

journal article

Pramlintide acetate in the treatment of Type 2 and Type 1 diabetes mellitus.

Published in:

Expert Review of Endocrinology & Metabolism, 2007, v. 2, n. 1, p. 9, doi. 10.1586/17446651.2.1.9

By:

Edelman, Steven V.;
Schroeder, Brock E.;
Frias, Juan P.

Publication type:

Article

Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.

Published in:

Obesity (19307381), 2023, v. 31, n. 3, p. 703, doi. 10.1002/oby.23673

By:

Wharton, Sean;
Batterham, Rachel L.;
Bhatta, Meena;
Buscemi, Silvio;
Christensen, Louise N.;
Frias, Juan P.;
Jódar, Esteban;
Kandler, Kristian;
Rigas, Georgia;
Wadden, Thomas A.;
Garvey, W. Timothy

Publication type:

Article

Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11.

Published in:

Diabetes Therapy, 2021, v. 12, n. 10, p. 2783, doi. 10.1007/s13300-021-01140-9

By:

Van, Joanna;
Frias, Juan P.;
Bonora, Enzo;
Raha, Sohini;
Meyer, Jarrett;
Jung, Heike;
Cox, David;
Konig, Manige;
Peleshok, Jennifer;
Bethel, M. Angelyn

Publication type:

Article

Correction to: Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.

Published in:

2020

By:

Guja, Cristian;
Frías, Juan P.;
Suchower, Lisa;
Hardy, Elise;
Marr, Galina;
Sjöström, C. David;
Jabbour, Serge A.

Publication type:

Correction Notice

Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.

Published in:

Diabetes Therapy, 2020, v. 11, n. 7, p. 1467, doi. 10.1007/s13300-020-00815-z

By:

Guja, Cristian;
Frías, Juan P.;
Suchower, Lisa;
Hardy, Elise;
Marr, Galina;
Sjöström, C. David;
Jabbour, Serge A.

Publication type:

Article

A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide.

Published in:

Diabetes Therapy, 2019, v. 10, n. 1, p. 21, doi. 10.1007/s13300-018-0547-5

By:

Frias, Juan P.;
Dex, Terry;
Roberts, Michelle;
Kaplan, Allen

Publication type:

Article

Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.

Published in:

JAMA: Journal of the American Medical Association, 2023, v. 330, n. 17, p. 1631, doi. 10.1001/jama.2023.20294

By:

Rosenstock, Julio;
Frías, Juan P.;
Rodbard, Helena W.;
Tofé, Santiago;
Sears, Emmalee;
Huh, Ruth;
Fernández Landó, Laura;
Patel, Hiren

Publication type:

Article

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.

Published in:

2021

By:

Wadden, Thomas A.;
Bailey, Timothy S.;
Billings, Liana K.;
Davies, Melanie;
Frias, Juan P.;
Koroleva, Anna;
Lingvay, Ildiko;
O'Neil, Patrick M.;
Rubino, Domenica M.;
Skovgaard, Dorthe;
Wallenstein, Signe O. R.;
Garvey, W. Timothy;
STEP 3 Investigators

Publication type:

journal article

Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.

Published in:

Expert Review of Endocrinology & Metabolism, 2020, v. 15, n. 6, p. 379, doi. 10.1080/17446651.2020.1830759

By:

Frías, Juan P

Publication type:

Article

Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial.

Published in:

Diabetes Care, 2023, v. 46, n. 5, p. 1060, doi. 10.2337/dc22-2396

By:

Bue-Valleskey, Juliana M.;
Kazda, Christof M.;
Ma, Chenchen;
Chien, Jenny;
Zhang, Qianyi;
Chigutsa, Emmanuel;
Landschulz, William;
Haupt, Axel;
Frias, Juan P.

Publication type:

Article

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program.

Published in:

Diabetes Care, 2022, v. 45, n. 10, p. 2396, doi. 10.2337/dc21-1785

By:

Perreault, Leigh;
Davies, Melanie;
Frias, Juan P.;
Laursen, Peter Nørkjaer;
Lingvay, Ildiko;
Machineni, Sriram;
Varbo, Anette;
Wilding, John P.H.;
Wallenstein, Signe Olrik Rytter;
le Roux, Carel W.

Publication type:

Article

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11).

Published in:

2021

By:

Frias, Juan P.;
Bonora, Enzo;
Nevarez Ruiz, Luis;
Li, Ying G.;
Yu, Zhuoxin;
Milicevic, Zvonko;
Malik, Raleigh;
Bethel, M. Angelyn;
Cox, David A.

Publication type:

journal article

Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D.

Published in:

2020

By:

Blevins, Thomas;
Zhang, Qianyi;
Frias, Juan P.;
Jinnouchi, Hideaki;
Chang, Annette M.;
PRONTO-T2D Investigators

Publication type:

journal article

Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.

Published in:

2020

By:

Jabbour, Serge A.;
Frías, Juan P.;
Ahmed, Azazuddin;
Hardy, Elise;
Choi, Jasmine;
Sjöström, C. David;
Guja, Cristian

Publication type:

journal article

Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study.

Published in:

2020

By:

Pettus, Jeremy H.;
D’Alessio, David;
Frias, Juan P.;
Vajda, Eric G.;
Pipkin, James D.;
Rosenstock, Julio;
Williamson, Gretchen;
Zangmeister, Miriam A.;
Lin Zhi;
Marschke, Keith B.;
D'Alessio, David;
Zhi, Lin

Publication type:

journal article

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.

Published in:

2018

By:

Jabbour, Serge A.;
Frías, Juan P.;
Hardy, Elise;
Hui Wang;
Öhman, Peter;
Ahmed, Azazuddin;
Guja, Cristian;
Wang, Hui

Publication type:

journal article

More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.

Published in:

2018

By:

Rosenstock, Julio;
Frías, Juan P.;
Roussel, Ronan;
Bolli, Geremia B.;
Cheng, Alice;
Ritzel, Robert;
Bosnyak, Zsolt;
Devisme, Christine;
Cali, Anna M.G.;
Sieber, Jochen;
Stella, Peter;
Xiangling Wang;
Wang, Xiangling

Publication type:

journal article

Review of Adverse Events Associated With False Glucose Readings Measured by GDH-PQQ-Based Glucose Test Strips in the Presence of Interfering Sugars.

Published in:

Diabetes Care, 2010, v. 33, n. 4, p. 728, doi. 10.2337/dc09-1822

By:

Frias, Juan P.;
Lim, Christine G.;
Ellison, John M.;
Montandon, Carol M.

Publication type:

Article

Anticipatory guidance in type 2 diabetes to improve disease management; next steps after basal insulin.

Published in:

2018

By:

Johnson, Eric L.;
Frias, Juan P.;
Trujillo, Jennifer M.

Publication type:

journal article

Pramlintide improved measures of glycemic control and body weight in patients With type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy.

Published in:

2013

By:

Herrmann, Kathrin;
Frias, Juan P;
Edelman, Steven V;
Lutz, Karen;
Shan, Kevin;
Chen, Steven;
Maggs, David;
Kolterman, Orville G

Publication type:

Journal Article

192-OR: Glycemic Control with Once-Weekly Basal Insulin Fc (BIF) in Persons with Type 2 Diabetes Mellitus (T2DM) Using Continuous Glucose Monitoring (CGM) in a Phase 2 Study.

Published in:

Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-192-OR

By:

KAZDA, CHRISTOF M.;
CHIEN, JENNY;
ZHANG, QIANYI;
CHIGUTSA, EMMANUEL;
LANDSCHULZ, WILLIAM;
WULLENWEBER, PAULA;
HAUPT, AXEL;
FRIAS, JUAN P.

Publication type:

Article